Role of platelet rich plasma (PRP) in the treatment of male type baldness

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

February 24, 2018

Last Updated

4 years ago

Study Type

Interventional

Sponsor

•1\.All the patients not using topical minoxidil and finasteride for at least 6 months will be considered for PRP therapy.
•2\.Age group 20 â?? 60 years
•3\.Sex\- Male
•4\.Mild to moderate AGA (Hamilton\-Norwood score II\-V) .
•5\.Patients willing to come for follow up every month for 5 months.

•1\.Patients not giving informed written consent, unable to understand the protocol and uncooperative patients.
•2\.Any inflammation, erythema or scarring over scalp except mild seborrheic dermatitis.
•3\.Patients who have history of malignancies, platelets disorders or bleeding disorders, anemia ( haemoglobulin of less than 10 gm/dl), bone marrow aplasia, diabetes, sepsis, and cancer.
•4\.Patients taking theses any of these medications\-
•i.Anti\-coagulants â?? heparin, warfarin
•ii.Anti\-hypertensives â?? beta\-blockers, ACE inhibitors hormones
•iii.Anticonvulsants â?? valproic acid, carbamazepine, phenytoin, mood stabilizers Antidepressants, lithium
•iv.Aspirin or any non\-steroidal anti\-inflammatory drugs two week prior to procedure.
•v.Other medications cimetidine, retinoids (acitretin \> isotretinoin), antithyroid drugs, cholesterol lowering drugs, interferons, amphetamines, bromocriptine, levodopa, some antipsychotic and anti\-anxiety drugs, rarely tricyclic antidepressants such as amitriptyline
•5\.Patients who are known to be HIV, hepatitis B or C positive or otherwise immunocompromised.